2.09
price up icon6.63%   0.13
after-market アフターアワーズ: 2.11 0.02 +0.96%
loading
前日終値:
$1.96
開ける:
$2
24時間の取引高:
4.12M
Relative Volume:
1.43
時価総額:
$243.61M
収益:
$6.65M
当期純損益:
$-136.32M
株価収益率:
-1.821
EPS:
-1.1477
ネットキャッシュフロー:
$-112.04M
1週間 パフォーマンス:
+6.09%
1か月 パフォーマンス:
+20.81%
6か月 パフォーマンス:
+99.05%
1年 パフォーマンス:
+72.73%
1日の値動き範囲:
Value
$1.93
$2.14
1週間の範囲:
Value
$1.86
$2.1591
52週間の値動き範囲:
Value
$0.91
$2.88

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
名前
Fate Therapeutics Inc
Name
セクター
Healthcare (1104)
Name
電話
858.875.1803
Name
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
職員
161
Name
Twitter
@fatethx
Name
次回の収益日
2026-08-11
Name
最新のSEC提出書
Name
FATE's Discussions on Twitter

Compare FATE vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
FATE icon
FATE
Fate Therapeutics Inc
2.09 243.61M 6.65M -136.32M -112.04M -1.1477
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
451.63 114.63B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
609.94 63.95B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
877.72 54.58B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
278.09 37.13B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
162.99 34.65B 742.00K -1.37B -1.07B -7.0731

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-05-19 再開されました Jefferies Buy
2025-10-31 アップグレード H.C. Wainwright Neutral → Buy
2025-10-27 アップグレード Wedbush Neutral → Outperform
2024-11-18 アップグレード BofA Securities Underperform → Neutral
2024-06-17 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-24 ダウングレード H.C. Wainwright Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2023-01-06 ダウングレード Cowen Outperform → Market Perform
2023-01-06 ダウングレード Piper Sandler Overweight → Neutral
2023-01-06 ダウングレード Stifel Buy → Hold
2023-01-06 ダウングレード Truist Buy → Hold
2023-01-06 ダウングレード Wedbush Outperform → Neutral
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-12-22 ダウングレード Oppenheimer Outperform → Perform
2022-12-15 開始されました Goldman Sell
2022-11-04 再開されました Cantor Fitzgerald Overweight
2022-10-10 開始されました Canaccord Genuity Buy
2022-08-18 再開されました Wells Fargo Overweight
2022-07-28 開始されました Needham Hold
2022-07-11 アップグレード BMO Capital Markets Market Perform → Outperform
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-11 再開されました BMO Capital Markets Market Perform
2021-12-15 アップグレード Wedbush Neutral → Outperform
2021-12-07 開始されました Cowen Outperform
2021-11-09 アップグレード Citigroup Neutral → Buy
2021-08-26 開始されました Morgan Stanley Equal-Weight
2021-06-07 アップグレード H.C. Wainwright Neutral → Buy
2021-05-07 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Jefferies Buy
2021-02-26 開始されました BofA Securities Buy
2021-02-26 ダウングレード Wedbush Outperform → Neutral
2021-02-11 ダウングレード Citigroup Buy → Neutral
2021-01-27 再開されました H.C. Wainwright Neutral
2020-05-13 開始されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-09 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-12-30 繰り返されました Mizuho Buy
2019-12-09 アップグレード Wells Fargo Market Perform → Outperform
2019-11-12 開始されました SunTrust Buy
2019-11-06 ダウングレード Wells Fargo Outperform → Market Perform
2019-10-01 開始されました Stifel Buy
2019-08-09 開始されました BTIG Research Buy
2019-07-22 開始されました Cantor Fitzgerald Overweight
2019-07-12 開始されました Oppenheimer Outperform
2019-06-13 開始されました Mizuho Buy
2019-06-07 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Buy
2019-05-24 再開されました Citigroup Buy
2019-03-28 開始されました SVB Leerink Outperform
2019-01-03 ダウングレード Stephens Overweight → Equal-Weight
2018-11-05 開始されました Jefferies Buy
2018-08-01 開始されました Citigroup Buy
2018-03-06 ダウングレード H.C. Wainwright Buy → Neutral
すべてを表示

Fate Therapeutics Inc (FATE) 最新ニュース

pulisher
Jun 18, 2026

Fate Therapeutics Inc (FATE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Fate Therapeutics Inc (FATE) Institutional Confidence - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Fate Therapeutics Inc (FATE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Fate Therapeutics Inc (FATE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Fate Therapeutics Inc (FATE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Fate Therapeutics Inc (FATE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Fate Therapeutics Inc (FATE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 18, 2026
pulisher
Jun 16, 2026

Fate Therapeutics Inc (FATE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 16, 2026
pulisher
Jun 15, 2026

Redmile director nominee awarded 87,900 Fate Therapeutics (FATE) stock options - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Fate Therapeutics (FATE) director granted 87,900 stock options at $2.06 - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Director Yuan Xu receives 87,900 Fate Therapeutics (FATE) stock options at $2.06 - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

FATE Therapeutics (NASDAQ: FATE) director awarded 87,900 stock options as equity pay - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Fate Therapeutics (FATE) director receives 87,900 stock options at $2.06 strike - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Fate Therapeutics (FATE) director receives 87,900 stock options award - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

FATE Therapeutics (NASDAQ: FATE) director receives 87,900-share stock option grant - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Director at Fate Therapeutics (NASDAQ: FATE) receives 87,900 stock options grant - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Director Laura Hamill receives 175,800 Fate Therapeutics (FATE) stock options - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Director Laura Hamill files initial Form 3 for FATE Therapeutics (FATE) - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

[8-K] FATE THERAPEUTICS INC Reports Material Event - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Fate Therapeutics Inc Stock (US3025491025): valuation focus as clinical-stage biotech trades near lo - AD HOC NEWS

Jun 15, 2026
pulisher
Jun 15, 2026

Fate Therapeutics Appoints Laura Hamill To Board Of Directors - TradingView

Jun 15, 2026
pulisher
Jun 15, 2026

Fate Therapeutics appoints Laura Hamill to board of directors - Investing.com

Jun 15, 2026
pulisher
Jun 15, 2026

Fate Therapeutics, Inc. (FATE) Latest Stock News & Headlines - Yahoo Finance

Jun 15, 2026
pulisher
Jun 15, 2026

Fate Therapeutics Appoints Laura Hamill to Board of Directors - GlobeNewswire

Jun 15, 2026
pulisher
Jun 13, 2026

Fate Therapeutics (FATE) Q1 2026 Earnings: EPS Beat on Cost Discipline, Pipeline Progress Drives Stock HigherSegment Revenue Breakdown - newsline.com

Jun 13, 2026
pulisher
Jun 12, 2026

FATE Stock Price, Quote & Chart - ChartMill

Jun 12, 2026
pulisher
Jun 11, 2026

FATE SEC FilingsFate Therapeutic 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 11, 2026
pulisher
Jun 10, 2026

H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT - Insider Monkey

Jun 10, 2026
pulisher
Jun 10, 2026

5 Hot Biotech Stocks Under $5 to Buy - Insider Monkey

Jun 10, 2026
pulisher
Jun 10, 2026

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.

Jun 10, 2026
pulisher
Jun 09, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jun 09, 2026
pulisher
Jun 08, 2026

FATE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $7.00 - GuruFocus

Jun 08, 2026
pulisher
Jun 08, 2026

H.C. Wainwright reiterates Fate Therapeutics stock rating on SLE data By Investing.com - Investing.com Canada

Jun 08, 2026
pulisher
Jun 05, 2026

Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6 - Moomoo

Jun 05, 2026
pulisher
Jun 04, 2026

Fate Therapeutics Advances Off-the-Shelf CAR T-Cell Therapies for Autoimmune Diseases and Cancer – Clinical Pipeline and 2026 Updates - Minichart

Jun 04, 2026
pulisher
Jun 04, 2026

Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline - TipRanks

Jun 04, 2026
pulisher
Jun 04, 2026

Fate Therapeutics updates corporate presentation; highlights FT819 Phase 1/2 progress, FT836 enrollment, $174.8M cash - TradingView

Jun 04, 2026
pulisher
Jun 04, 2026

Fate Therapeutics (NASDAQ: FATE) details FT819, FT836 data and cash runway into 2028 - Stock Titan

Jun 04, 2026
pulisher
Jun 04, 2026

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting - markets.businessinsider.com

Jun 04, 2026
pulisher
Jun 04, 2026

Fate Therapeutics presents autoimmune therapy data at EULAR - Investing.com

Jun 04, 2026
pulisher
Jun 04, 2026

Fate Therapeutics presents autoimmune therapy data at EULAR By Investing.com - Investing.com South Africa

Jun 04, 2026
pulisher
Jun 04, 2026

Fate Therapeutics Showcases Data from FT819 and FT839 - GlobeNewswire

Jun 04, 2026
pulisher
Jun 03, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 03, 2026
pulisher
Jun 02, 2026

LCTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Jun 02, 2026
pulisher
Jun 01, 2026

Off-the-shelf FT836 shrinks tumors in colorectal cancer without conditioning chemo - Stock Titan

Jun 01, 2026
pulisher
Jun 01, 2026

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting - GlobeNewswire

Jun 01, 2026
pulisher
May 30, 2026

Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely? - Yahoo Finance

May 30, 2026
pulisher
May 29, 2026

The $13 Million Company Teaching the Immune System to Hunt Cancer - Quantisnow

May 29, 2026
pulisher
May 27, 2026

Fate Therapeutics Rallies 9.5% as FATE Stock Breaks Above Key Support LevelShort Setup Alerts - newsline.com

May 27, 2026
pulisher
May 26, 2026

H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7 - Moomoo

May 26, 2026

Fate Therapeutics Inc (FATE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$31.43
price up icon 0.74%
$90.89
price down icon 1.44%
$52.96
price down icon 1.38%
$63.96
price up icon 3.50%
ONC ONC
$270.15
price up icon 2.84%
$162.99
price up icon 3.31%
大文字化:     |  ボリューム (24 時間):